Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

NCT02693171 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT02693171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02693171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
Lead sponsor
United Therapeutics
Phase
Observational
Overall status
Terminated
Start date
March 15, 2016
Completion date
December 19, 2016
Enrollment
13 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma